Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | PLK1 | P53350 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10988244 | 0.94 | CYP3A4 (0.50) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL1007565 | 0.91 | LTA4H (0.53) | LTA4HCA12CA1CA2CA7 | |
| SCHEMBL949228 | 0.88 | NR5A1 (0.58) | LTA4HL3MBTL1LMNANPC1MAPT | |
| SCHEMBL20969950 | 0.86 | PRSS1 (0.41) | CA12CA1CA2CA9MAPT | |
| SCHEMBL2832393 | 0.86 | NR5A1 (0.61) | LTA4HL3MBTL1LMNANPC1MAPT | |
| SCHEMBL946779 | 0.86 | NR5A1 (0.61) | LTA4HL3MBTL1LMNANPC1MAPT | |
| SCHEMBL948700 | 0.86 | NR5A1 (0.61) | LTA4HL3MBTL1LMNANPC1MAPT | |
| SCHEMBL9706419 | 0.86 | NR5A1 (0.61) | LTA4HL3MBTL1LMNANPC1MAPT | |
| SCHEMBL10993242 | 0.86 | CYP2D6 (0.59) | LTA4HL3MBTL1NPC1HPGDRAB9A | |
| SCHEMBL4748828 | 0.86 | NR5A1 (0.61) | LTA4HL3MBTL1LMNANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025048243-A1 | NOVEL ISOXAZOLE COMPOUND AS TM4SF5-SPECIFIC INHIBITOR AND USE THEREOF | 서울대학교산학협력단 | 2025-03-06 | — | — | WO | disclosed |
| EP-3733186-B1 | NOVEL DIHYDROQUINAZOLINONE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT, AND CELL GROWTH INHIBITOR | JAPANESE FOUND FOR CANCER RES (JP) | 2024-12-04 | — | — | EP | disclosed |
| US-11566017-B2 | Dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor | RIKEN (JP) | 2023-01-31 | — | — | US | disclosed |
| US-20210061789-A1 | NOVEL DIHYDROQUINAZOLINONE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT, AND CELL GROWTH INHIBITOR | RIKEN (JP) | 2021-03-04 | — | — | US | disclosed |
| EP-3733186-A1 | NOVEL DIHYDRO-QUINAZOLINONE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF, AND CELL GROWTH INHIBITOR | RIKEN (JP) | 2020-11-04 | — | — | EP | disclosed |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2018-11-22 | — | — | US | disclosed |
| US-20180086979-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-03-29 | — | — | US | disclosed |
| EP-1763509-B1 | ALPHA-HELICAL MIMETICS | WALTER & ELIZA HALL INST MEDICAL RES (AU) | 2018-02-21 | — | — | EP | disclosed |
| US-9896479-B2 | Functionalized naphthalene fluorophores | Kay M. Brummond (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2440245-B1 | BENZONAPHTHYRIDINE-CONTAINING VACCINES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-12-06 | — | — | EP | disclosed |
| WO-2005012280-A1 | ALKYNYL ARYL CARBOXAMIDES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2005-02-10 | — | — | WO | disclosed |
| EP-1274713-B1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIV CARDIFF (GB) | 2004-03-10 | — | — | EP | disclosed |
| EP-1375463-A1 | OPTICALLY ACTIVE COMPOUND AND PHOTOSENSITIVE RESIN COMPOSITION | Kansai Research Institute, Inc. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | KRI, INC. (JP) | 2003-11-13 | — | — | US | disclosed |
| US-20030148967-A1 | Anti-viral pyrimidine nucleoside analogues | REGA FOUNDATION (BE) | 2003-08-07 | — | — | US | disclosed |
| EP-1274713-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | University College Cardiff Consultants Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| WO-2001083501-A1 | ANTI-VIRAL PYRIMIDINE NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2001-11-08 | — | — | WO | disclosed |
| EP-0597701-B1 | Conjugated enyne derivative and liquid crystal composition | CHISSO CORP (JP) | 1997-04-16 | — | — | EP | disclosed |
| US-5370819-A | Low viscosity | CHISSO CORPORATION (JP) | 1994-12-06 | — | — | US | disclosed |
| EP-0597701-A1 | Conjugated enyne derivative and liquid crystal composition | CHISSO CORPORATION (JP) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061789-A1 | NOVEL DIHYDROQUINAZOLINONE COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT, AND CELL GROWTH INHIBITOR | MKI67, CCNI, NHERF1 | LTA4H 4407/4885CA12 1887/4885CA1 1463/4885 |
| US-20030148967-A1 | Anti-viral pyrimidine nucleoside analogues | NUDT1, DNTT, RNMT | LTA4H 2687/4885CA12 2264/4885CA1 3448/4885 |
| US-11566017-B2 | Dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor | MKI67, CCNI, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LTA4H 4415/4885CA12 1568/4885CA1 1322/4885 |
| US-20180333406-A1 | BENZONAPTHYRIDINE COMPOSITIONS AND USES THEREOF | HAMP, MAVS, MYD88 | LTA4H 2416/4885CA12 3836/4885CA1 4263/4885 |
| US-20030211421-A1 | Optically active compound and photosensitive resin composition | ARCN1, RAD51, PAM | LTA4H 1238/4885CA12 4194/4885CA1 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.